Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

ABSTRACT: Source data for the main figures 1, 3, 4, and 6 for manuscript ID: EMM-2025-23148-T.

ORGANISM(S): Homo sapiens (human)

SUBMITTER: Subha Baniya

PROVIDER: S-BSST2770 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description: Not available

| S-SCDT-10_1038-S44321-026-00421-9 | biostudies-other

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description:The systemic administration of therapeutic agents, particularly large, charged molecules such as antibodies, has limited efficacy in treating central nervous system (CNS) disorders. In addition, the slow progression of neurodegenerative diseases makes repeated intrathecal injections unfeasible. Alzheimer’s disease is characterized by the accumulation of Aβ amyloid plaques. Microglia contribute to the clearance of Aβ, but are inhibited by the expression of CD33. Therefore, antibody blocking of CD33 may enhance the phagocytosis of Aβ by microglial cells, slowing AD progression. Here, we use cells as “targeted cellular micropharmacies” that are retained in the CNS to deliver therapeutic proteins directly into the brain. To achieve this, we genetically engineered CD4 T-cells to express: (1) a chimeric antigen receptor against GD2 to retain the cells into the brain, (2) ectopic FoxP3 to reduce inflammation, (3) secreted IL-2 to promote cell longevity, and (4) secreted anti-CD33 scFv antibody. Our proof-of-concept demonstrates that therapeutic antibodies can be delivered to the brain for at least 8 weeks to treat neurological disorders. Other agents could be similarly delivered into the brain by this platform.

2026-03-17 | GSE321698 | GEO

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description: Not available

| S-BIAD2997 | bioimages

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description:Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

| PRJNA1429318 | ENA

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

Project description:Aurora kinase A (AURKA) is a well-established target in neuroblastoma (NB) due to both its catalytic functions during mitosis and its kinase-independent functions, including stabilization of the key oncoprotein MYCN. We present a structure-activity relationship (SAR) study of MK-5108-derived PROTACs against AURKA by exploring different linker lengths and exit vectors on the thalidomide moiety. PROTAC SK2188 induces the most potent AURKA degradation (DC50,24h 3.9 nM, Dmax,24h 89%) and shows an excellent binding and degradation selectivity profile. Treatment of NGP neuroblastoma cells with SK2188 induced concomitant MYCN degradation, high replication stress/DNA damage levels and apoptosis. Moreover, SK2188 significantly outperforms the parent inhibitor MK-5108 in a cell proliferation screen and patient-derived organoids. Furthermore, altering the attachment point of the PEG linker to the 5-position of thalidomide allowed us to identify a potent AURKA degrader with a linker as short as 2 PEG units. With this, our SAR-study provides interesting lead structures for further optimization and validation of AURKA degradation as a potential therapeutic strategy in neuroblastoma

2023-02-27 | PXD040391 | Pride

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

2023-02-27 | PXD040389 | Pride

YY1 downregulation underlies therapeutic response to molecular targeted agents.

Project description: Not available

| S-EPMC11603335 | biostudies-literature

Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents.

Project description: Not available

| S-EPMC7407834 | biostudies-literature

New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.

Project description: Not available

| S-EPMC9658349 | biostudies-literature